异环磷酰胺自1988年被美国FDA批准上市以来,常与其他抗癌药物联合用于恶性淋巴瘤及其他实体瘤的治疗,效果值得肯定。但其不良反应在一定程度上限制了该药的应用。已知异环磷酰胺的不良反应包括血液学毒性、尿路毒性及中枢神经系统毒性等。国内关于异环磷酰胺所致的中枢神经系统毒性(亦称“脑病”)仅有零星报道。我们报道1例难治性淋巴瘤患者,先后2次在含有异环磷 Ifosfamide since the FDA approved the listing in 1988, often associated with other anti-cancer drugs for the treatment of malignant lymphoma and other solid tumors, the effect is worthy of recognition. However, its adverse reactions to a certain extent limit the application of the drug. Adverse reactions of ifosfamide are known to include hematologic toxicity, urinary tract toxicity and central nervous system toxicity. National on ifosfamide-induced central nervous system toxicity (also known as “encephalopathy”) only sporadic reports. We report a case of refractory lymphoma patients, has 2 times containing isoflorate